Incluye referencias bibliográficas

Preface; Contents; Part I: Hematopoiesis; Chapter 1: Hematopoietic Stem Cells: The Basis of Normal and Malignant Hematopoiesis; 1.1 Introduction; 1.2 Hematopoietic Stem Cells in Normal Hematopoiesis; 1.2.1 Shifting Site of Hematopoiesis; 1.2.2 Identification of HSCs; 1.2.3 Transcriptional Control of HSCs: Hematopoietic Hierarchies and Lineage Determination; 1.2.4 Microenvironment of HSCs: The Niche; 1.3 Stem Cells in Abnormal Hematopoiesis; 1.3.1 Disruption of Transcription Network Leads to Hematopoietic Malignancy; 1.3.2 Cancer Stem Cells and Xenograft Transplantation Models.

1.3.3 Preleukemic Stem Cells as the Reservoir of LSCs1.3.4 In Utero Generation of Pre-LSCs/LSCs in Childhood Leukemia; 1.3.5 Genetic Profiles of Leukemic Stem Cells and Their Progeny; 1.3.6 Clonal Evolution of Preleukemic Cells to Leukemic Stem Cells; 1.4 Characteristics of Leukemic Stem Cells; 1.4.1 Leukemic Stem Cells in AML; 1.4.2 Leukemic Stem Cells in Acute Lymphoid Leukemia (ALL); 1.4.3 Clinical Implications and Future Directions; References; Part II: White Blood Cell Disorders; Chapter 2: Acute Lymphoblastic Leukemia; 2.1 Introduction; 2.2 Epidemiology; 2.3 Pathobiology.

2.3.1 Aneuploidy2.3.1.1 Hyperdiploidy; 2.3.1.2 Hypodiploidy; 2.3.2 Structural Chromosomal Abnormalities; 2.3.2.1 ETV6-RUNX1 (TEL-AML1); 2.3.2.2 TCF3-PBX1 (E2A-PBX1); 2.3.2.3 KMT2A (MLL) Gene Rearrangements; 2.3.2.4 BCR-ABL1; 2.3.2.5 Philadelphia (Ph)-like ALL; 2.3.2.6 iAMP21; 2.3.2.7 IKZF1, CRLF2, and JAK; 2.3.2.8 ETP-ALL; 2.3.2.9 Genetic Alterations at Relapse; 2.4 Clinical Management; 2.4.1 Clinical Presentation; 2.4.2 Diagnostic Procedures; 2.4.3 Treatment; 2.4.3.1 Prognostic Factors; Clinical Features at Initial Diagnosis; Biologic and Genetic Features; Early Treatment Response.

2.4.3.2 Chemotherapy for ALL Remission-Induction Therapy; Consolidation Therapy; Maintenance Therapy; 2.4.3.3 CNS-Directed Therapy; 2.4.3.4 Hematopoietic Stem Cell Transplantation; 2.4.3.5 Special Subcategories; Down Syndrome ALL; Adolescent and Young Adults with ALL; 2.5 Future Challenges; References; Chapter 3: Acute Myeloid Leukemia; 3.1 Introduction; 3.2 Diagnosis of Acute Myeloid Leukemia; 3.3 Treatment of De Novo AML; 3.3.1 Prognostic Factors; 3.3.1.1 Biologic and Genetic Features; 3.3.1.2 Early Treatment Response; 3.3.2 AML Therapy; 3.3.2.1 Remission-Induction Phase.

3.3.2.2 Post-Remission Phase3.3.3 Novel Therapeutic Approach for AML; 3.4 Myeloid Leukemia Associated with Down Syndrome; 3.5 Acute Promyelocytic Leukemia; References; Chapter 4: Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML); 4.1 Introduction; 4.2 Pediatric MDS; 4.2.1 Epidemiology; 4.2.2 Classification; 4.2.3 Clinical and Laboratory Characteristics; 4.2.4 Morphology and Histology; 4.2.5 Cytogenetics; 4.2.6 Pathobiology; 4.2.7 Differential Diagnosis; 4.2.8 Management and Treatment; 4.3 Juvenile Myelomonocytic Leukemia; 4.3.1 Epidemiology; 4.3.2 Classification.

This book describes the pathogenesis and treatment of several representative hematological disorders in children, with a special focus on genetic and molecular aspects. Research on the pathogenesis of hematological disorders in children has made remarkable strides; especially molecular target therapy has shown outstanding effects in refractory and conventional therapies for childhood leukemia. The findings presented in this book will broaden readers' understanding and hopefully spark new discussions leading to the development of new therapies including cell therapy and molecular target therapy, allowing clinicians to use more effective and less toxic approaches in the future. Hematological Disorders in Children will appeal to a wide readership, from medical students and beginning investigators to experienced scholars in the field of pediatric hematology and oncology seeking to broaden their understanding and keep up with the latest developments. It will also be of interest to the parents of pediatric patients, and to co-medical staffs.